Liraglutide Improves Diabetic Cardiomyopathy by Downregulation of Cardiac Inflammatory and Apoptosis Markers.

Q3 Medicine

Current Drug Research Reviews Pub Date : 2024-01-01 DOI:10.2174/0125899775243787231103075804

Polly Gupta, Rustam Ekbbal

{"title":"Liraglutide Improves Diabetic Cardiomyopathy by Downregulation of Cardiac Inflammatory and Apoptosis Markers.","authors":"Polly Gupta, Rustam Ekbbal","doi":"10.2174/0125899775243787231103075804","DOIUrl":null,"url":null,"abstract":"Background: Diabetic cardiomyopathy is one of the leading causes of mortality for people with diabetes worldwide. The majority of the formalistic alterations in the heart associated with diabetic cardiomyopathy have been found to be primarily caused by the ongoing oxidative stress brought on by hyperglycemia, which leads to the dysfunctional reactions of apoptosis and inflammation. Liraglutide, a long-acting counterpart of glucagon-like peptide-1, has been demonstrated to have a number of therapeutic applications in medicine and other biological processes.Methods: The PubMed database was searched using the terms liraglutide, DCM, and all associated inflammatory markers.Results: There has been a lot of research on liraglutide's potential to protect the heart from cardiomyopathy brought on by diabetes. Liraglutide's therapeutic actions as an antioxidant, antihyperglycemic, anti-apoptotic, and anti-inflammatory medicine may help to lessen diabetic cardiomyopathy.Conclusion: The most recent studies on the effects of liraglutide therapy on DCM are presented in this review, along with an explanation of the underlying mechanisms.","PeriodicalId":37008,"journal":{"name":"Current Drug Research Reviews","volume":" ","pages":"289-299"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Drug Research Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0125899775243787231103075804","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Diabetic cardiomyopathy is one of the leading causes of mortality for people with diabetes worldwide. The majority of the formalistic alterations in the heart associated with diabetic cardiomyopathy have been found to be primarily caused by the ongoing oxidative stress brought on by hyperglycemia, which leads to the dysfunctional reactions of apoptosis and inflammation. Liraglutide, a long-acting counterpart of glucagon-like peptide-1, has been demonstrated to have a number of therapeutic applications in medicine and other biological processes.

Methods: The PubMed database was searched using the terms liraglutide, DCM, and all associated inflammatory markers.

Results: There has been a lot of research on liraglutide's potential to protect the heart from cardiomyopathy brought on by diabetes. Liraglutide's therapeutic actions as an antioxidant, antihyperglycemic, anti-apoptotic, and anti-inflammatory medicine may help to lessen diabetic cardiomyopathy.

Conclusion: The most recent studies on the effects of liraglutide therapy on DCM are presented in this review, along with an explanation of the underlying mechanisms.

查看原文本刊更多论文

利拉鲁肽通过下调心脏炎症和凋亡标志物改善糖尿病心肌病。

背景:糖尿病性心肌病是全世界糖尿病患者死亡的主要原因之一。大多数与糖尿病性心肌病相关的心脏形态改变主要是由高血糖引起的持续氧化应激引起的，氧化应激导致细胞凋亡和炎症的功能失调反应。利拉鲁肽是胰高血糖素样肽-1的长效对应物，已被证明在医学和其他生物过程中具有许多治疗应用。方法:使用利拉鲁肽、DCM和所有相关炎症标志物检索PubMed数据库。结果:关于利拉鲁肽保护心脏免受糖尿病引起的心肌病的潜力已经有了大量的研究。利拉鲁肽作为抗氧化、降糖、抗凋亡和抗炎药物的治疗作用可能有助于减轻糖尿病性心肌病。结论:本文综述了利拉鲁肽治疗DCM的最新研究，并对其潜在机制进行了解释。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Drug Research Reviews Medicine-Psychiatry and Mental Health

CiteScore

3.70

自引率

0.00%

发文量